title: Plasma lipoprotein lipase, hepatic lipase activities, VLDL, LDL compositions at different times of hemodialysis.
abstract: The effects of hemodialysis duration (HD) on lipoprotein lipase (LPL) and hepatic lipase (HL) activities and very low density lipoprotein (VLDL), low density lipoproteins (LDL) amounts and compositions were investigated in 58 patients, divided according to HD: GI: under 1 year, GII: 1-5 years, GIII: 5-13 years. HL and LPL activities were reduced in GIII versus GI (P<0.01) and 47% of GIII patients had negligible HL activity. LPL and HL activities were correlated with HD (r=-0.80, P<0.001). Apo C-III concentrations were correlated with HD (r=0.58, P<0.05). Compared with controls, triacylglycerols (TG) were increased in GI, GII (P<0.01) and GIII (P<0.001), and were correlated with HD (r=0.75, P<0.05). VLDL amounts and VLDL-cholesteryl esters (CE) were enhanced in GIII versus GI and GII (P<0.05). VLDL-TG and VLDL-phospholipids (PL) were correlated with HD (r=0.60, P<0.05). LDL-apolipoproteins and unesterified cholesterol (UC) were increased in GII versus GI (P<0.05) and in GIII versus GII and GI (P<0.01). LDL-PLs were decreased in GIII versus GI (P<0.05). Compared with controls, LDL-TGs were higher in GI and GII (P<0.01) and in GIII (P<0.05). Long-term treatment with acetate hemodialysis using cuprophane membrane does not improve lipolytic activity decrease and lipoprotein alterations generated by chronic renal failure (CRF).
authors.affiliation: Laboratoire de Nutrition Clinique et Métabolique, Département de Biologie, Faculté des Sciences, Université d'Oran-31000 Es-Sénia, Oran, Algeria.
authors.forename: Khedidja
authors.initials: K
authors.lastname: Mekki
authors.forename: Josiane
authors.initials: J
authors.lastname: Prost
authors.forename: Malika
authors.initials: M
authors.lastname: Bouchenak
authors.forename: Mustapha
authors.initials: M
authors.lastname: Remaoun
authors.forename: Jacques
authors.initials: J
authors.lastname: Belleville
mesh_terms: D000328:Adult; D001053:Apolipoproteins / Q000097:blood; D002482:Cellulose / Q000031:analogs & derivatives*; D002784:Cholesterol / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008049:Lipase / Q000097:blood*; D008071:Lipoprotein Lipase / Q000032:analysis / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000097:blood*; D008099:Liver / Q000201:enzymology*; D008297:Male; D008567:Membranes, Artificial; D010743:Phospholipids / Q000097:blood; D006435:Renal Dialysis / Q000295:instrumentation; D014280:Triglycerides / Q000097:blood
chemical_list: D001053:Apolipoproteins; D015243:Cholesterol, VLDL; D007328:Insulin; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D008567:Membranes, Artificial; D010743:Phospholipids; D014280:Triglycerides; D002482:Cellulose; C009865:cuprammonium cellulose; D002784:Cholesterol; D008049:Lipase; D008071:Lipoprotein Lipase